Swiss drug maker Roche (OTCQX: RHHBY) announced a stock split earlier this month. The ADR will split in the ratio of 2:1 effective Feb 27, 2014.
Here are the details from the...(read more
Roche (RHHBY) recently announced positive data on its ulcerative colitis (UC) candidate, etrolizumab (RG7413), from EUCALYPTUS, a phase II induction study (n=124).
The study is...(read more
Pfizer Inc. (PFE) recently faced a pipeline setback with the company discontinuing a late-stage study being conducted with its oncology candidate, inotuzumab ozogamicin.
The randomized,...(read more